Literature DB >> 7536098

Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs.

K H Banner1, C P Page.   

Abstract

1. The aims of this study were to determine which phosphodiesterase (PDE) isoenzymes are involved in the control of eosinophil accumulation in the airways of ovalbumin (OVA)-immunized guinea-pigs by the use of isoenzyme selective inhibitors and to compare the effects of acute versus chronic administration of PDE isozyme inhibitors on pulmonary cell influx in ovalbumin-immunized guinea-pigs. 2. Guinea-pigs were sensitized and subsequently challenged with aerosolized OVA. Twenty four hours later bronchoalveolar lavage (BAL) was performed to permit assessment of inflammatory cell accumulation. A significant increase in the number of eosinophils was observed in the lavage fluid from OVA-immunized (13.6 +/- 1.4 x 10(4) ml-1 in acute experiments and 10.1 +/- 1.4 x 10(4) ml-1 in chronic experiments) animals compared with sham-treated controls (5.6 +/- 0.6 x 10(4) ml-1 in acute experiments and 5.1 +/- 0.6 x 10(4) ml-1 in chronic experiments). There was no difference in neutrophil, mononuclear cell or total cell numbers between the two groups. 3. Acute administration of a high dose of selective and non-selective PDE inhibitors by the i.p. route had no significant effect on eosinophil accumulation in the airways. 4. Chronic administration of a low dose (3 mg kg-1, i.p., twice daily for 7 days) of the type IV PDE inhibitor, RO 20-1724, and the PDE III/IV inhibitor, zardaverine, produced a significant inhibition of eosinophil accumulation (46% and 59% respectively). 5. These results suggest that the type IV PDE isoenzyme plays a role in the control of allergen-induced eosinophil infiltration into the airways, but indicate that a period of low dose chronic treatment with a type IV or mixed type III/IV PDE inhibitor is necessary for eosinophil accumulation in the airways to be reduced.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536098      PMCID: PMC1510161          DOI: 10.1111/j.1476-5381.1995.tb14910.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide.

Authors:  S M Wellicome; M H Thornhill; C Pitzalis; D S Thomas; J S Lanchbury; G S Panayi; D O Haskard
Journal:  J Immunol       Date:  1990-04-01       Impact factor: 5.422

Review 2.  Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.

Authors:  C D Nicholson; R A Challiss; M Shahid
Journal:  Trends Pharmacol Sci       Date:  1991-01       Impact factor: 14.819

Review 3.  The role of the eosinophil in the pathogenesis of asthma.

Authors:  A J Wardlaw; A B Kay
Journal:  Allergy       Date:  1987-07       Impact factor: 13.146

Review 4.  Pharmacologic management of reversible obstructive airways disease.

Authors:  M Weinberger; L Hendeles; R Ahrens
Journal:  Med Clin North Am       Date:  1981-05       Impact factor: 5.456

5.  Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells.

Authors:  C Lugnier; V B Schini
Journal:  Biochem Pharmacol       Date:  1990-01-01       Impact factor: 5.858

6.  Effect of theophylline and adenosine on eosinophil function.

Authors:  T Yukawa; C Kroegel; P Chanez; G Dent; D Ukena; K F Chung; P J Barnes
Journal:  Am Rev Respir Dis       Date:  1989-08

Review 7.  The eosinophil and the pathophysiology of asthma.

Authors:  E Frigas; G J Gleich
Journal:  J Allergy Clin Immunol       Date:  1986-04       Impact factor: 10.793

Review 8.  The effects of theophylline on airway inflammation.

Authors:  R Pauwels
Journal:  Chest       Date:  1987-07       Impact factor: 9.410

9.  Cyclic adenosine 3':5'-monophosphate phosphodiesterase. Distinct forms in human lymphocytes and monocytes.

Authors:  W J Thompson; C P Ross; W J Pledger; S J Strada; R L Banner; E M Hersh
Journal:  J Biol Chem       Date:  1976-08-25       Impact factor: 5.157

Review 10.  Overview of effects of theophylline.

Authors:  C G Persson
Journal:  J Allergy Clin Immunol       Date:  1986-10       Impact factor: 10.793

View more
  7 in total

1.  Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.

Authors:  D M Hammerbeck; S M McGurran; P L Radziszewski; E A Egging; D D Johnson; A M Hupperts; G W Gullikson
Journal:  Inflammation       Date:  2000-08       Impact factor: 4.092

2.  Anti-inflammatory effects of theophylline, cromolyn and salbutamol in a murine model of pleurisy.

Authors:  T S Saleh; J B Calixto; Y S Medeiros
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

3.  Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs.

Authors:  J L Ortiz; J M Vallés; M Martí-Cabrera; J Cortijo; E J Morcillo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-01       Impact factor: 3.000

4.  Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits.

Authors:  N Gozzard; A el-Hashim; C M Herd; S M Blake; M Holbrook; B Hughes; G A Higgs; C P Page
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

5.  Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects.

Authors:  H Tenor; A Hatzelmann; M K Church; C Schudt; J K Shute
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

6.  Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits.

Authors:  N Gozzard; C M Herd; S M Blake; M Holbrook; B Hughes; G A Higgs; C P Page
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

Review 7.  New Avenues for Phosphodiesterase Inhibitors in Asthma.

Authors:  Maria Gabriella Matera; Josuel Ora; Francesco Cavalli; Paola Rogliani; Mario Cazzola
Journal:  J Exp Pharmacol       Date:  2021-03-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.